Barts Health NHS Trust launches app for cognitively impairedAn app to support people with cognitive disabilities, developed with clinicians at Barts Health NHS Trust, has started Share XBarts Health NHS Trust launches app for cognitively impairedhttps://pharmaphorum.com/news/barts-health-nhs-trust-launches-app-for-cognitively-impaired/
Keytruda’s liver cancer approval secured by new studyMerck & Co’s FDA approval for Keytruda in advanced liver cancer looks secure, after an Asian clinical trial Share XKeytruda’s liver cancer approval secured by new studyhttps://pharmaphorum.com/news/keytrudas-liver-cancer-approval-secured-by-new-study/
Sanofi abandons mRNA COVID jab, despite positive trialSanofi has said that it won’t develop its mRNA-based vaccine for COVID-19 any further, even though it seemed Share XSanofi abandons mRNA COVID jab, despite positive trialhttps://pharmaphorum.com/news/sanofi-abandons-mrna-covid-jab-despite-positive-trial/
Biogen, Eisai double down on Alzheimer’s with lecanemab filingBiogen and Eisai’s first Alzheimer’s disease drug Aduhelm is facing an uphill battle in the US market, but Share XBiogen, Eisai double down on Alzheimer’s with lecanemab filinghttps://pharmaphorum.com/news/biogen-eisai-double-down-on-alzheimers-with-lecanemab-filing/
Bad news for Biohaven as verdiperstat flunks first phase 3 testBiohaven’s key pipeline drug verdiperstat has failed to have any Therapeutic effect in patients with the rare neurological Share XBad news for Biohaven as verdiperstat flunks first phase 3 testhttps://pharmaphorum.com/news/bad-news-for-biohaven-as-verdiperstat-flunks-first-phase-3-test/
Takeda bags Japanese approval for Crohn’s cell therapy AlofiselTakeda has chalked up another milestone for its Alofisel cell therapy for a complication of Crohn’s disease, becoming Share XTakeda bags Japanese approval for Crohn’s cell therapy Alofiselhttps://pharmaphorum.com/news/takeda-bags-japanese-approval-for-crohns-cell-therapy-alofisel/
England’s cancer therapy backlog ‘could take more than a decade to shift’A new report has suggested it could take until 2033 to clear the backlog of cancer treatment in Share XEngland’s cancer therapy backlog ‘could take more than a decade to shift’https://pharmaphorum.com/news/englands-cancer-therapy-backlog-could-take-more-than-a-decade-to-shift/
YonaLink, TrialJectory get $1m grant for patient recruitment toolTwo digital health companies – YonaLink and TrialJectory – have received a grant to develop a tool designed Share XYonaLink, TrialJectory get $1m grant for patient recruitment toolhttps://pharmaphorum.com/news/yonalink-trialjectory-get-1m-grant-for-patient-recruitment-tool/
Capricor preps phase 3 for Duchenne cell therapy as it seeks a partnerCapricor Therapeutics’ bid to find a partner for its Duchenne muscular dystrophy (DMD) cell therapy CAP-1002 could get Share XCapricor preps phase 3 for Duchenne cell therapy as it seeks a partnerhttps://pharmaphorum.com/news/capricor-preps-phase-3-for-duchenne-cell-therapy-as-it-seeks-a-partner/
